{"product_id":"wegovy-semaglutida-flex-touch-solucion-1mg-dosis-con-1","title":"Wegovy (Semaglutide) FlexTouch Solution 1mg\/dose Pen with 1ml","description":"\u003ch2\u003eCategory\u003c\/h2\u003e\n\u003cp\u003eMedication\u003c\/p\u003e\n\n\u003ch2\u003eLine\u003c\/h2\u003e\n\u003cp\u003eWegovy\u003c\/p\u003e\n\n\u003ch2\u003eBrand\u003c\/h2\u003e\n\u003cp\u003eNovo Nordisk\u003c\/p\u003e\n\n\u003ch2\u003eMolecule\u003c\/h2\u003e\n\u003cp\u003eSemaglutide\u003c\/p\u003e\n\n\u003ch2\u003ePresentation\u003c\/h2\u003e\n\u003cp\u003e1 mg\/dose solution in Flex Touch device.\u003c\/p\u003e\n\n\u003ch2\u003eLaboratory\u003c\/h2\u003e\n\u003cp\u003eNovo Nordisk\u003c\/p\u003e\n\n\u003ch2\u003eIndications\u003c\/h2\u003e\n\u003cp\u003eWegovy (Semaglutide) is indicated as an adjunct to a reduced-calorie diet and increased physical activity for the treatment of obesity in adults and adolescents aged 12 years and older. This medication is used in patients with a body mass index (BMI) of 30 kg\/m² or greater, or in those with a BMI of 27 kg\/m² or greater who have at least one weight-related comorbidity, such as hypertension, type 2 diabetes, or dyslipidemia. Wegovy works by regulating appetite and food intake, which facilitates weight loss and helps maintain the achieved weight.\u003c\/p\u003e\n\n\u003ch2\u003eComposition\u003c\/h2\u003e\n\u003cp\u003eEach dose of Wegovy contains 1 mg of Semaglutide, in addition to excipients that facilitate its formulation and administration.\u003c\/p\u003e\n\n\u003ch2\u003eContraindications\u003c\/h2\u003e\n\u003cp\u003eWegovy is contraindicated in patients with a history of hypersensitivity to Semaglutide or to any of the excipients in the formulation. It is also contraindicated in patients with a history of acute pancreatitis and in those with a family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 syndrome.\u003c\/p\u003e\n\n\u003ch2\u003ePrecautions\u003c\/h2\u003e\n\u003cp\u003eCaution should be exercised when administering Wegovy to patients with a history of pancreatic disease, kidney disease, or liver disease. It is important to monitor renal function in patients experiencing dehydration due to adverse gastrointestinal effects. It is recommended to assess the risk of hypoglycemia in patients receiving concomitant treatment with insulin or medications that increase insulin secretion.\u003c\/p\u003e\n\n\u003ch2\u003eStorage\u003c\/h2\u003e\n\u003cp\u003eThe medication should be stored refrigerated between 2°C and 8°C. Do not freeze. Once opened, the Flex Touch device can be stored at room temperature (up to 30°C) for a maximum of 28 days.\u003c\/p\u003e\n\n\u003cp\u003ePrescription required.\u003c\/p\u003e\n\u003cp\u003eConsult your doctor.\u003c\/p\u003e","brand":"Novo Nordisk","offers":[{"title":"Default Title","offer_id":46313589899489,"sku":"7503007822963","price":6184.69,"currency_code":"MXN","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0722\/1500\/3361\/files\/optimized_wegovy_semaglutida_flex_touch_solucion_1mgdosis_pluma_con_1ml_7503007822963_1.jpg?v=1768503928","url":"https:\/\/wecarepharma.mx\/en\/products\/wegovy-semaglutida-flex-touch-solucion-1mg-dosis-con-1","provider":"WeCare Pharma","version":"1.0","type":"link"}